Business Context and Reporting Period
Company: Organogenesis Holdings Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: September 25, 2025
Subject: Update on the second Phase 3 randomized controlled trial (RCT) of ReNu, a cryopreserved amniotic suspension allograft (ASA) for knee osteoarthritis (OA).
Key Financial Metrics
This filing is a current report regarding clinical trial results and regulatory strategy. It does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial metrics.
Material Changes and Clinical Results
- Second Phase 3 RCT Outcome: The fully enrolled 594-patient trial did not achieve statistical significance for its primary endpoint.
- Primary Endpoint Data: The study measured the difference in knee pain reduction at six months using the WOMAC pain scale. ReNu showed a numerical improvement of -0.5 over saline (p=0.0393 one-sided), which missed the target threshold of p=0.023.
- Comparison to First Phase 3 Trial: The first Phase 3 trial achieved statistical significance with an improvement of -0.7 (p=0.0177). However, baseline pain reduction at six months was numerically higher in the second trial (-6.9) compared to the first (-6.0).
- Safety Profile: ReNu continued to demonstrate a favorable safety profile in the second trial.
Guidance, Outlook, and Risks
- Regulatory Strategy: The Company plans to request a pre-Biologics License Application (BLA) meeting with the FDA by the end of October 2025.
- Submission Pathway: Management intends to discuss using a combined efficacy analysis from both Phase 3 studies to support BLA approval.
- Risks and Uncertainties:
- The FDA may require additional evidence before accepting a BLA.
- Future clinical trials may produce different results.
- Uncertainty regarding market acceptance, reimbursement from third-party payers (including Medicare/Medicaid), and commercial success.
- Potential for unforeseen safety issues or manufacturing challenges.
Investor Verification Checklist
- Verify the specific criteria the FDA will require for a combined efficacy analysis of the two Phase 3 trials.
- Monitor the outcome of the pre-BLA meeting scheduled for late October 2025.
- Review the detailed data in Exhibit 99.2 regarding the statistical analysis of the second Phase 3 RCT.
- Assess the impact of the non-significant primary endpoint on the timeline and probability of regulatory approval.
- Confirm the Company's cash runway and capital requirements given the potential need for additional studies or delayed commercialization.